STOCK TITAN

[144] PTC THERAPEUTICS, INC. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

PTC Therapeutics, Inc. submitted a Form 144 disclosing a proposed sale of 22,655 common shares through Fidelity Brokerage Services LLC on 10/03/2025 with an aggregate market value of $1,491,104.96. The filing reports the shares were acquired under an option granted on 01/05/2023 and will be sold for cash. The issuer's outstanding shares are listed as 79,438,094.

The filing also lists prior sales by the same person in the past three months: 2,813 shares on 08/15/2025 (gross proceeds $136,646.54), 22,664 shares on 09/11/2025 (gross proceeds $1,382,537.63), and 24,585 shares on 09/12/2025 (gross proceeds $1,508,093.64). The filer attests there is no undisclosed material adverse information.

PTC Therapeutics, Inc. ha presentato una Form 144 che comunica una vendita proposta di 22.655 azioni ordinarie tramite Fidelity Brokerage Services LLC in data 10/03/2025 con un valore complessivo di mercato di $1,491,104.96. La registrazione riporta che le azioni sono state acquisite nell’ambito di una opzione concessa il 01/05/2023 e saranno vendute in contanti. Le azioni in circolazione dell’emittente sono riportate come 79,438,094.

La registrazione elenca anche le vendite precedenti effettuate dalla stessa persona negli ultimi tre mesi: 2,813 azioni il 08/15/2025 (proventi lordi $136,646.54), 22,664 azioni il 09/11/2025 (proventi lordi $1,382,537.63) e 24,585 azioni il 09/12/2025 (proventi lordi $1,508,093.64). Il dichiarante attesta che non esistono informazioni avverse materiali non disclose.

PTC Therapeutics, Inc. presentó un Formulario 144 divulgando una venta propuesta de 22,655 acciones comunes a través de Fidelity Brokerage Services LLC el 10/03/2025 con un valor de mercado total de $1,491,104.96. El escrito informa que las acciones fueron adquiridas bajo una opción otorgada el 01/05/2023 y se venderán por efectivo. Las acciones en circulación de la emitriz se enumeran como 79,438,094.

El escrito también lista ventas anteriores realizadas por la misma persona en los últimos tres meses: 2,813 acciones el 08/15/2025 (ingresos brutos $136,646.54), 22,664 acciones el 09/11/2025 (ingresos brutos $1,382,537.63), y 24,585 acciones el 09/12/2025 (ingresos brutos $1,508,093.64). El declarante certifica que no hay información material adversa no divulgada.

PTC Therapeutics, Inc.Form 144를 제출하여 Fidelity Brokerage Services LLC를 통해 22,655주 보통주를 2025-10-03에 매각하려는 제안되는 거래를 공시했습니다. 총 시장가치는 $1,491,104.96입니다. 이 제출서는 주식이 부여된 옵션 하에 2023-01-05에 취득되었으며 현금으로 매각될 예정임을 보고합니다. 발행사의 발행주식 수는 79,438,094 주로 기재되어 있습니다.

또한 같은 사람의 지난 3개월간의 이전 매도 내역도 기재되어 있습니다: 2,813주를 2025-08-15, 순매출액 $136,646.54로, 22,664주를 2025-09-11, 순매출액 $1,382,537.63로, 그리고 24,585주를 2025-09-12, 순매출액 $1,508,093.64로 매도했습니다. 작성자는 미공개의 중요 악정보가 없다고 확인합니다.

PTC Therapeutics, Inc. a soumis un formulaire 144 divulguant une vente proposée de 22 655 actions ordinaires via Fidelity Brokerage Services LLC le 03/10/2025 avec une valeur marchande globale de $1 491 104,96. Le dépôt indique que les actions ont été acquises dans le cadre d’une option accordée le 05/01/2023 et seront vendues en argent comptant. Le nombre d’actions en circulation de l’émetteur est indiqué comme 79 438 094.

Le dépôt répertorie également les ventes antérieures par la même personne au cours des trois derniers mois: 2 813 actions le 15/08/2025 (produits bruts $136 646,54), 22 664 actions le 11/09/2025 (produits bruts $1 382 537,63) et 24 585 actions le 12/09/2025 (produits bruts $1 508 093,64). Le déclarant atteste qu’il n’y a aucune information négative matérielle non divulguée.

PTC Therapeutics, Inc. hat ein Formular 144 eingereicht, das einen vorgeschlagenen Verkauf von 22.655 Stammaktien über Fidelity Brokerage Services LLC am 03.10.2025 mit einem gesamten Marktwert von $1.491.104,96 offenbart. Die Einreichung berichtet, dass die Aktien unter einer am 01.05.2023 gewährten Option erworben wurden und in bar verkauft werden sollen. Die ausstehende Aktienanzahl des Emittenten ist mit 79.438.094 angegeben.

Die Einreichung listet außerdem frühere Verkäufe derselben Person in den letzten drei Monaten auf: 2.813 Aktien am 15.08.2025 (Bruttoerlöse $136.646,54), 22.664 Aktien am 11.09.2025 (Bruttoerlöse $1.382.537,63) und 24.585 Aktien am 12.09.2025 (Bruttoerlöse $1.508.093,64). Der Meldende bestätigt, dass es keine unausgeschöpften wesentlichen nachteiligen Informationen gibt.

PTC Therapeutics, Inc. قدمت نموذج 144 يكشف عن بيع مقترح لـ 22,655 سهمًا عاديًا من خلال Fidelity Brokerage Services LLC في 03/10/2025 مع قيمة سوقية إجمالية قدرها $1,491,104.96. التقرير يذكر أن الأسهم تمتلك بموجب خيار ممنوح في 01/05/2023 وسيتم بيعها النقدًا. أسهم المصدر المعلقة مدرجة كـ 79,438,094.

كما يورد التقرير مبيعات سابقة من نفس الشخص خلال الثلاثة أشهر الماضية: 2,813 سهمًا في 08/15/2025 بإيرادات إجمالية قدرها $136,646.54، و22,664 سهمًا في 09/11/2025 بإيرادات إجمالية قدرها $1,382,537.63، و24,585 سهمًا في 09/12/2025 بإيرادات إجمالية قدرها $1,508,093.64. يؤكد الملزم أنه لا توجد معلومات سلبية مادية غير مُعلنة.

PTC Therapeutics, Inc. 提交了 Form 144,披露通过 Fidelity Brokerage Services LLC2025/10/03 提议出售 22,655 股普通股,交易的总市场价值为 $1,491,104.96。申报中显示这些股票是在 2023/01/05 授予的 期权 下取得,拟以 现金 方式出售。发行人流通股数列为 79,438,094 股。

申报还列出该人过去三个月内的前次出售:2,813 股,日期为 2025/08/15,毛收入 $136,646.5422,664 股,日期为 2025/09/11,毛收入 $1,382,537.63;以及 24,585 股,日期为 2025/09/12,毛收入 $1,508,093.64。申报人声称不存在未披露的重大不利信息。

Positive
  • Form 144 filed demonstrating compliance with Rule 144 disclosure requirements
  • Sale details disclosed: broker (Fidelity), exact share count (22,655), sale date (10/03/2025), and aggregate market value ($1,491,104.96)
  • Acquisition method disclosed (option granted 01/05/2023) and cash payment indicated
Negative
  • None.

Insights

TL;DR: Insider filed a standard Rule 144 notice for a scheduled sale of 22,655 shares on 10/03/2025.

The Form 144 shows the securities were acquired via an option granted on 01/05/2023 and the planned sale will be executed through Fidelity Brokerage Services LLC for cash. The filing includes the issuer's total outstanding shares of 79,438,094, which provides context for the sale's size.

This notice is a regulatory disclosure required before certain insider sales; it documents recent insider transactions including three sales totaling 50,062 shares in the prior three months with combined reported gross proceeds of $3,027,277.81, as shown in the filing.

PTC Therapeutics, Inc. ha presentato una Form 144 che comunica una vendita proposta di 22.655 azioni ordinarie tramite Fidelity Brokerage Services LLC in data 10/03/2025 con un valore complessivo di mercato di $1,491,104.96. La registrazione riporta che le azioni sono state acquisite nell’ambito di una opzione concessa il 01/05/2023 e saranno vendute in contanti. Le azioni in circolazione dell’emittente sono riportate come 79,438,094.

La registrazione elenca anche le vendite precedenti effettuate dalla stessa persona negli ultimi tre mesi: 2,813 azioni il 08/15/2025 (proventi lordi $136,646.54), 22,664 azioni il 09/11/2025 (proventi lordi $1,382,537.63) e 24,585 azioni il 09/12/2025 (proventi lordi $1,508,093.64). Il dichiarante attesta che non esistono informazioni avverse materiali non disclose.

PTC Therapeutics, Inc. presentó un Formulario 144 divulgando una venta propuesta de 22,655 acciones comunes a través de Fidelity Brokerage Services LLC el 10/03/2025 con un valor de mercado total de $1,491,104.96. El escrito informa que las acciones fueron adquiridas bajo una opción otorgada el 01/05/2023 y se venderán por efectivo. Las acciones en circulación de la emitriz se enumeran como 79,438,094.

El escrito también lista ventas anteriores realizadas por la misma persona en los últimos tres meses: 2,813 acciones el 08/15/2025 (ingresos brutos $136,646.54), 22,664 acciones el 09/11/2025 (ingresos brutos $1,382,537.63), y 24,585 acciones el 09/12/2025 (ingresos brutos $1,508,093.64). El declarante certifica que no hay información material adversa no divulgada.

PTC Therapeutics, Inc.Form 144를 제출하여 Fidelity Brokerage Services LLC를 통해 22,655주 보통주를 2025-10-03에 매각하려는 제안되는 거래를 공시했습니다. 총 시장가치는 $1,491,104.96입니다. 이 제출서는 주식이 부여된 옵션 하에 2023-01-05에 취득되었으며 현금으로 매각될 예정임을 보고합니다. 발행사의 발행주식 수는 79,438,094 주로 기재되어 있습니다.

또한 같은 사람의 지난 3개월간의 이전 매도 내역도 기재되어 있습니다: 2,813주를 2025-08-15, 순매출액 $136,646.54로, 22,664주를 2025-09-11, 순매출액 $1,382,537.63로, 그리고 24,585주를 2025-09-12, 순매출액 $1,508,093.64로 매도했습니다. 작성자는 미공개의 중요 악정보가 없다고 확인합니다.

PTC Therapeutics, Inc. a soumis un formulaire 144 divulguant une vente proposée de 22 655 actions ordinaires via Fidelity Brokerage Services LLC le 03/10/2025 avec une valeur marchande globale de $1 491 104,96. Le dépôt indique que les actions ont été acquises dans le cadre d’une option accordée le 05/01/2023 et seront vendues en argent comptant. Le nombre d’actions en circulation de l’émetteur est indiqué comme 79 438 094.

Le dépôt répertorie également les ventes antérieures par la même personne au cours des trois derniers mois: 2 813 actions le 15/08/2025 (produits bruts $136 646,54), 22 664 actions le 11/09/2025 (produits bruts $1 382 537,63) et 24 585 actions le 12/09/2025 (produits bruts $1 508 093,64). Le déclarant atteste qu’il n’y a aucune information négative matérielle non divulguée.

PTC Therapeutics, Inc. hat ein Formular 144 eingereicht, das einen vorgeschlagenen Verkauf von 22.655 Stammaktien über Fidelity Brokerage Services LLC am 03.10.2025 mit einem gesamten Marktwert von $1.491.104,96 offenbart. Die Einreichung berichtet, dass die Aktien unter einer am 01.05.2023 gewährten Option erworben wurden und in bar verkauft werden sollen. Die ausstehende Aktienanzahl des Emittenten ist mit 79.438.094 angegeben.

Die Einreichung listet außerdem frühere Verkäufe derselben Person in den letzten drei Monaten auf: 2.813 Aktien am 15.08.2025 (Bruttoerlöse $136.646,54), 22.664 Aktien am 11.09.2025 (Bruttoerlöse $1.382.537,63) und 24.585 Aktien am 12.09.2025 (Bruttoerlöse $1.508.093,64). Der Meldende bestätigt, dass es keine unausgeschöpften wesentlichen nachteiligen Informationen gibt.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What did PTC Therapeutics (PTCT) disclose in the Form 144?

The Form 144 discloses a proposed sale of 22,655 common shares through Fidelity on 10/03/2025 with an aggregate market value of $1,491,104.96.

How were the shares being sold by the PTCT filer acquired?

The filing states the shares were acquired via an option granted on 01/05/2023 and the sale consideration is cash.

Does the filing show other recent insider sales for PTCT?

Yes. The filer sold 2,813 shares on 08/15/2025 (proceeds $136,646.54), 22,664 shares on 09/11/2025 (proceeds $1,382,537.63), and 24,585 shares on 09/12/2025 (proceeds $1,508,093.64).

What is the issuer's total shares outstanding reported in the filing?

The Form 144 lists the issuer's shares outstanding as 79,438,094.

Who is the broker handling the proposed sale in the Form 144?

The broker named in the filing is Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, RI.
Ptc Therapeutics

NASDAQ:PTCT

PTCT Rankings

PTCT Latest News

PTCT Latest SEC Filings

PTCT Stock Data

5.08B
77.43M
2.47%
101.79%
8.36%
Biotechnology
Pharmaceutical Preparations
Link
United States
WARREN